RT Journal Article
SR Electronic
T1 Agios Exits Oncology
JF Cancer Discovery
JO Cancer Discov
FD American Association for Cancer Research
DO 10.1158/2159-8290.CD-NB2021-0303
YR 2021
UL http://cancerdiscovery.aacrjournals.org/content/early/2021/01/26/2159-8290.CD-NB2021-0303.abstract
AB Agios Pharmaceuticals, the company behind the only two IDH-targeted drugs on the market and a brain-penetrant IDH inhibitor in late-stage testing for glioma, announced plans to sell its oncology business to Servier for up to $2 billion plus royalties.